A Comparison of Transversus Abdominis Plane Blocks Versus Continuous Intravenous Lidocaine for Kidney Transplant Surgery
Overview
- Phase
- Phase 2
- Intervention
- Transversus Abdominis Plane Block
- Conditions
- Postoperative Pain
- Sponsor
- Benaroya Research Institute
- Enrollment
- 124
- Locations
- 1
- Primary Endpoint
- Opioid Consumption
- Last Updated
- 6 years ago
Overview
Brief Summary
This study will compare continuous intravenous lidocaine against single-injection transversus abdominis plane (TAP) block as a modality for postoperative analgesia in kidney transplant surgery.
Detailed Description
This study is a non-inferiority trial designed to assess the analgesic efficacy of an intravenous (IV) lidocaine infusion against single-injection transversus abdominis plane (TAP) block in patients undergoing kidney transplant surgery. The investigators propose a study of 124 subjects randomized into two groups. The control group will receive a TAP block. The study group will receive a continuous IV lidocaine infusion. The investigators hypothesize that there will be no statistically significant difference in postoperative opioid consumption between the two groups in the first 24 hours.
Investigators
Neil Hanson
Anesthesiologist
Benaroya Research Institute
Eligibility Criteria
Inclusion Criteria
- •Kidney transplant recipient
- •\>18 years old
- •Consent to participate
Exclusion Criteria
- •\<18 years old
- •Refusal to participate
- •Chronic opioid use
- •Seizure disorder
- •Allergy to local anesthestics
- •Severe hepatic disease
Arms & Interventions
TAP Block
Single-injection transversus abdominis plane block
Intervention: Transversus Abdominis Plane Block
IV Lidocaine
Continuous intravenous lidocaine infusion
Intervention: Intravenous Lidocaine
Outcomes
Primary Outcomes
Opioid Consumption
Time Frame: 0-24 Hours
Total opioid utilization
Secondary Outcomes
- Pain Scores(0-48 Hours)
- Opioid Consumption(24-48 Hours)
- Opioid-Related Adverse Events(0-48 Hours)
- Block/Infusion-Related Adverse Events(0-48 Hours)
- Opioid Usage(30 days from discharge)